Greg Howland

Abbvie
Cicero, United States

Zinayida Schlachetzki

United States

Deepti Cole

Brighton, United States

PAPER Ivanova A, Murphy M

An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations.

J Biopharm Stat. 2009;19(2):247-55. PubMed: 19212877

PAPER Alfa Cissé M, Sunyach C, Slack BE, Fisher A, Vincent B, Checler F

M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity.

J Neurosci. 2007 Apr 11;27(15):4083-92. PubMed: 17428986

Philip Scheltens on FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.

COMMENT Without knowing the specifics of this, I would say, in general, that this move by the FDA is to be commended. For any laboratory test, one should be guaranteed that it has been developed with scientific rigor and that any patient should be able to rely on

Lira Janbolot

53840 Troisdorf, Germany

Jake Ellis-Williams

Bristol, United Kingdom

Mariam Gouda

Amsterdam university medical center
Amsterdam , Netherlands

PAPER Cohen ME, Shechter Y, Eichel R, Yahalom G

A benign course of Parkinson's disease associated with different mutations in the glucocerebrosidase gene- A case series.

Parkinsonism Relat Disord. 2024 May 4;124:106990. PubMed: 38735164

PAPER Barati N, Shojaeian A, Ramezani M, Kalhori F, Bazl MS, Zafari S, Asl SS, Motavallihaghi S

Investigating the effect of parasites (toxoplasma gondii RH strain, Leishmania major (MRHO/IR/75/ER), and hydatid cyst) antigens on Alzheimer's disease: An in vivo evaluation.

Exp Neurol. 2024 May 10;:114813. PubMed: 38735456

PAPER Hermann P, Zerr I

Unmet needs of biochemical biomarkers for human prion diseases.

Prion. 2024 Dec;18(1):89-93. Epub 2024 May 12 PubMed: 38734978

PAPER Kotredes KP, Pandey RS, Persohn S, Elderidge K, Burton CP, Miner EW, Haynes KA, Santos DF, Williams SP, Heaton N, Ingraham CM, Lloyd C, Garceau D, O'Rourke R, Herrick S, Rangel-Barajas C, Maharjan S, Wang N, Sasner M, Lamb BT, Territo PR, Sukoff Rizzo SJ, Carter GW, Howell GR, Oblak AL

Characterizing molecular and synaptic signatures in mouse models of late-onset Alzheimer's disease independent of amyloid and tau pathology.

Alzheimers Dement. 2024 May 12; PubMed: 38735056

PAPER Marzban S, Dastgheib Z, Lithgow B, Moussavi Z

Using principal component analysis to determine which vestibular stimuli provide best biomarkers for separating Alzheimer's from mixed Alzheimer's disease.

Med Biol Eng Comput. 2024 May 13; PubMed: 38735986

PAPER Wahl D, Grant RA, LaRocca TJ

The reverse transcriptase inhibitor 3TC modulates hippocampal transcriptome signatures of inflammation in tauopathy model mice.

Exp Gerontol. 2024 May 10;:112458. PubMed: 38735597